SUBSCRIBE
SUBSCRIBE

Mozart Therapeutics

IN THE PRESS
Drug Development
Mozart Therapeutics Announces Oral Presentation on MTX-101 at the 2024 American Diabetes Association’s 84th Scientific Sessions
June 21, 2024
 · 
2 min read
Drug Development
Mozart Therapeutics Doses First Cohort of Participants in Phase 1a/b Clinical Trial of MTX-101, in Development for Treatment of Autoimmune Diseases
June 17, 2024
 · 
2 min read
Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
May 24, 2024
 · 
5 min read
Drug Development
Mozart Therapeutics to Present Pre-clinical Data on KIR x ICOS CD8 Treg Modulator at Immunology 2024 Meeting
May 3, 2024
 · 
2 min read
BioForest
Mozart Therapeutics Presents Non-clinical Data on Lead Program, MTX-101 for Treatment of Autoimmune Diseases, at Society of Toxicology Annual Meeting 2024
March 14, 2024
 · 
2 min read
BioForest
Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel Bispecific CD8 Treg Modulator for Treatment of Autoimmune Diseases, at American College of Rheumatology Convergence 2023
November 13, 2023
 · 
2 min read
Business
Mozart Therapeutics Expands Executive Leadership Team with Appointments of Dr. Jason Chien, Chief Medical Officer, and Russ Hawkinson, Chief Financial Officer
October 30, 2023
 · 
2 min read
Drug Development
Mozart Therapeutics Presents Preclinical Data for MTX-101, a Novel CD8 Treg Network Modulator for Treatment of Autoimmune Disease, at FOCIS 2023 Annual Meeting
June 21, 2023
 · 
1 min read
BioForest
Mozart Therapeutics Raises $25 Million in Expanded Series A Financing to Support Clinical Development of First-in-Class CD8 Treg Modulators for the Treatment of Autoimmune Diseases
June 7, 2023
 · 
3 min read
BioForest
Mozart Therapeutics Highlights Promising Preclinical Activity of Novel CD8 Treg Network Modulator for Treatment of Autoimmune Diseases in Presentations at IMMUNOLOGY™ 2023
May 15, 2023
 · 
2 min read
Load More
JOBS